List of Vaccines Companies in Spain - 7

AELIX Therapeutics is a clinical-stage biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be included in cure/eradication strategies. AELIX Therapeutics is a spin-off of HIVACAT, the Catalan public-private consortium conducting cutting-edge research in this field. AELIX holds a worldwide, exclusive license for the development and commercialization of the HTI immunogen.

Araclon Biotech S.L. is a biotechnology company founded by Pr. Manuel Sarasa. Araclon Biotech is a company dedicated to the research and development of therapies and diagnostic methods to be applied to degenerative diseases, currently focusing on Alzheimer’s disease. At present, Araclon is working on four different projects: The first of these focuses on the diagnosis of Alzheimer’s disease (with a detection kit for beta-amyloid 40 and 42 proteins in blood already patented). The second is centred on Alzheimer’s therapy (immunotherapy based). The third is an emerging project, which attempts to respond to the challenge of predicting Alzheimer’s disease in totally asymptomatic individuals. And finally, a project related to the development of a therapy for the Parkinson’s disease. Our mission To research and develop immunotherapies and diagnostic methods used in the treatment of degenerative diseases. It is our aim to provide effective solutions for such diseases. Our objectives Within the area of degenerative diseases, we are currently focused on Alzheimer’s disease. As such, our initial objectives are: Validation and global marketing of a diagnostic blood test for Alzheimer’s disease. Development of effective immunotherapy against Alzheimer’s disease.

Archivel Farma is a biotech R&D company focused on the development of innovative immunotherapeutic products, notably in sterile, injectable and lyophilised products. Archivel Farma is currently developing, as its own project, RUTI®, a therapeutic vaccine for the treatment of active tuberculosis.

At Ferrer, we focus on identifying projects with differential value. The R&D team aims to develop and deliver transformative therapeutic solutions for people living with severe and debilitating diseases. Innovation is an inherent part of our pharmaceutical development, and we have always upheld our commitment in searching for and developing new treatment alternatives aimed at addressing unmet medical needs in order to improve the patients' quality of life and creating value for physicians, health systems and society at large. We do this in two main areas: Pulmonary vascular and interstitial lung diseases & Neurological disorders

INMUNOTEK is a pharma company which researches, develops, manufactures and distributes therapeutic vaccines in the fields of allergy, infectious diseases and cancer. In addition, the company develops, manufactures and sells medical devices. INMUNOTEK was founded in 1992 with the mission of improving the quality of life of patients and providing value to healthcare professionals, by creating innovative, safe and effective products. INMUNOTEK's products are sold in both Spain and in more than 50 other countries around the world through our subsidiaries, sales offices and exclusive distributors. Our two production centres are based in the towns of San Sebastián de los Reyes and Alcalá de Henares (Madrid, Spain).

A groundbreaking platform that extends the reach of genetic treatments by combining unprecedented DNA optimisation with non-viral delivery. Tyris Therapeutics has been founded to design the future of DNA-based treatments for patients suffering from life threatening diseases.

Headquartered in Seville, Spain, Vaxdyn works with an international network of collaborators in the development of multi-pathogen vaccines for preventing antibiotics-resistant infections in all regions of the world. Our vaccines target high-risk populations, population affected by chronic diseases of the lungs, liver, kidney, immunocompromised by co-morbidities like diabetes or cancer, populations associated with nursing homes and hospital settings, women affected by recurrent urinary-tract infections, or neonates. We are strongly committed to contribute to reducing antibiotic use in the world by following a One-Health approach. Vaxdyn is the first Spanish biotech funded by CARB-X. CARB-X awarded Vaxdyn in 2020 up to US$1.01 million, plus an additional $6.36 million if certain project milestones are met, to develop KapaVax until completion of the first proof of principle in humans (Phase 1). KapaVax is our first multi-valent candidate designed to raise immunity against Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, the top-3 superbacteria of urgent risk of the list of the World Health Organization (WHO).